The Asia-Pacific point-of-care diagnostics market is set to expand rapidly from 2025 to 2035, driven by the advancement of decentralized healthcare. The market is expected to reach USD 15.8 billion by 2035, with a CAGR of 13.45%.
The Asia-Pacific POCT market is strengthening its presence as a key market in the healthcare industry, driven by the advancement of decentralized healthcare, which brings the diagnostic capabilities of medical institutions closer to patients. This market forecast puts the market size at USD 38.27 billion in 2025, rising to USD 15.8 billion in 2035, with a CAGR of 13.45% over the period.
POCT is characterized by its ability to produce test results quickly near the point of care and link them to treatment decisions without relying on central laboratories. In the Asia-Pacific region, disparities in healthcare infrastructure between urban and rural areas will be a major factor shaping the market.
As demand expands beyond infectious diseases into diabetes, cardiovascular disease and cancer, testing systems capable of processing multiple parameters simultaneously, together with data connectivity and related services, will become increasingly important business models.
Market opportunities differ across China, India, Japan, South Korea and Southeast Asia, creating country-specific requirements for sales channels, pricing, regulatory compliance and support systems. For Japanese companies, investment strategies are expected to center on comprehensive diagnostic solutions that encompass not only testing equipment, but also reagents, digital connectivity and collaboration with local partners.